Skip to content
  • ENGLISHENGLISH
  • 繁體中文繁體中文
回首頁回首頁回首頁
  • About Alar
    • Company Profile
    • Leadership Team
    • History&Milestones
  • Products
    • Products Pipeline
    • Contract Manufacturing
  • Media
    • News
    • Event
    • Knowledge
  • Investors
    • Shareholder Services
    • Financials
    • Corporate Governance
  • Contact Us
MENU Close

2022/05/06 ALA-1000 Received notice of patent allowance from Intellectual Property Office of India , Application No. 201947006642

2022/05/06 ALA-1000 Received notice of patent allowance from Intellectual Property Office of India , Application No. 201947006642

  • Post author:alarpharm
  • Post published:9 . 5 . 2022
  • Post category:Media releases

You Might Also Like

2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients

10 . 3 . 2021

2022/04/21 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Singapore (IPOS), Application No. 11201901294Q.

21 . 4 . 2022

2021/10/29 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Vietnam, Application No. 1-2019-01258.

12 . 11 . 2021

2020/08/21 Alar Pharmaceuticals Inc. Completes Pre-IND Meeting with US FDA for ALA-3000

24 . 8 . 2020

2021/09/03 ALA-1000 Receive notice of patent allowance from Taiwan Intellectual Property Office (TIPO), Application No. 106131215.

7 . 9 . 2021
  • News
  • Event
  • Knowledge
回首頁

ABOUT

  • Company Profile
  • Leadership Team
  • History&Milestones
  • Company Profile
  • Leadership Team
  • History&Milestones

PRODUCTS

  • Products Pipeline
  • Contract Manufacturing
  • Products Pipeline
  • Contract Manufacturing

media

  • News
  • Event
  • Knowledge
  • News
  • Event
  • Knowledge

investors

  • Shareholder Services
  • Financials
  • Corporate Governance
  • Shareholder Services
  • Financials
  • Corporate Governance

CONTACT us

  • Contact Us
  • Contact Us
  • Contact Us
  • Privacy Policy
Copyright © - 2022 Alar Pharmaceuticals Inc . All right reserved.
Close
  • About Alar
    • Company Profile
    • Leadership Team
    • History&Milestones
  • Products
    • Products Pipeline
    • Contract Manufacturing
  • Media
    • News
    • Event
    • Knowledge
  • Investors
    • Shareholder
    • Financials
    • Corporate Governance
  • Contact Us
    • Contact Us
×

Cart